title: Glutathione S-transferase M1 null genotype related to poor prognosis of colorectal cancer.
abstract: Published studies showed controversial findings about the relationship between glutathione S-transferase M1 (GSTM1) null genotype and clinical outcomes of patients with colorectal cancer. We performed a meta-analysis to quantitatively assess the association between GSTM1 null genotype and prognosis of patients with colorectal cancer. We systematically searched Pubmed, Embase, and Web of Science to identify prospective or retrospective cohort studies assessing the association of GSTM1 null genotype with overall survival (OS) or disease-free survival (DFS) in colorectal cancer. The hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) were used to assess the association of GSTM1 null genotype with OS or DFS. Finally, 15 studies from 14 publications with 4326 colorectal cancer patients were included into the meta-analysis. There was no heterogeneity in the meta-analysis relating OS (I (2) = 0 %) and DFS (I (2) = 0 %). Overall, GSTM1 null genotype was significantly associated with poor OS in patients with colorectal cancer (HR = 1.18, 95 % CI 1.07-1.30, P = 0.001). In addition, GSTM1 null genotype was also significantly associated with poor DFS in patients with colorectal cancer (HR = 1.15, 95 % CI 1.03-1.28, P = 0.015). No obvious risk of publication bias was observed. GSTM1 null genotype is significantly associated with poor OS and DFS in patients with colorectal cancer, which suggests that GSTM1 null genotype confers poor effect on the prognosis of colorectal cancer.
authors.affiliation: Liver Transplantation Center of the First Affiliated Hospital, Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.|Department of Surgical Oncology, The Eighty-First Hospital of People's Liberation Army, Nanjing, 210002, China.|Department of Anorectal Surgery, the Affiliated Hospital of Weifang Medical University, Weifang, 261000, Shandong Province, China.
authors.forename: Shushan
authors.initials: S
authors.lastname: Yan
authors.affiliation: Department of Gynaecology and Obstetrics, Maternal and Children Health's Hospital, Weifang, 261011, China.
authors.forename: Zengfang
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Operating Room of People's Hospital of Zhucheng, Zhucheng, 262200, China.
authors.forename: Zengyan
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Surgical Oncology, The Eighty-First Hospital of People's Liberation Army, Nanjing, 210002, China. duanqh_doc@sina.com.
authors.forename: Quanhong
authors.initials: Q
authors.lastname: Duan
authors.affiliation: Liver Transplantation Center of the First Affiliated Hospital, Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.
authors.forename: Xiaochen
authors.initials: X
authors.lastname: Wang
authors.affiliation: Liver Transplantation Center of the First Affiliated Hospital, Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.|Department of General Surgery, the Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, 210000, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.affiliation: Liver Transplantation Center of the First Affiliated Hospital, Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu Province, China. beichengsun_doc@aliyun.com.
authors.forename: Beicheng
authors.initials: B
authors.lastname: Sun
mesh_terms: D015179:Colorectal Neoplasms / Q000235:genetics* / Q000401:mortality; D018572:Disease-Free Survival; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D005982:Glutathione Transferase / Q000235:genetics*; D006801:Humans; D011379:Prognosis
chemical_list: D005982:Glutathione Transferase
keywords: Colorectal cancer; Glutathione S-transferase M1; Prognosis
references.citation: Lancet. 2010 Mar 20;375(9719):1030-47
references.pmid: 20304247
references.citation: Cancer Epidemiol. 2009 Oct;33(3-4):249-56
references.pmid: 19748847
references.citation: Genet Mol Res. 2015 Aug 28;14(3):10236-41
references.pmid: 26345960
references.citation: Nat Rev Gastroenterol Hepatol. 2012 Dec;9(12):716-25
references.pmid: 23045000
references.citation: Expert Opin Drug Metab Toxicol. 2010 Feb;6(2):153-70
references.pmid: 20078251
references.citation: Clin Colorectal Cancer. 2013 Mar;12(1):8-14
references.pmid: 23102544
references.citation: Tumour Biol. 2014 Feb;35(2):949-53
references.pmid: 24014086
references.citation: Cancer Manag Res. 2013 Nov 19;5:377-85
references.pmid: 24399885
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: J Clin Oncol. 2007 Apr 1;25(10):1247-54
references.pmid: 17401013
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3227-33
references.pmid: 20530282
references.citation: Immunol Lett. 2002 May 1;81(3):159-64
references.pmid: 11947919
references.citation: Int J Oncol. 2006 Jan;28(1):231-6
references.pmid: 16328000
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120
references.citation: Pharmacogenomics. 2010 Jan;11(1):33-41
references.pmid: 20017670
references.citation: PLoS One. 2013 Jul 23;8(7):e69039
references.pmid: 23894404
references.citation: J Natl Cancer Inst. 2002 Jun 19;94(12):936-42
references.pmid: 12072547
references.citation: PLoS One. 2013 Apr 23;8(4):e61469
references.pmid: 23626689
references.citation: Pharmacogenet Genomics. 2014 Jul;24(7):340-7
references.pmid: 24842074
references.citation: Expert Rev Anticancer Ther. 2013 May;13(5):597-611
references.pmid: 23617351
references.citation: Pharmacoeconomics. 2013 Mar;31(3):215-28
references.pmid: 23338963
references.citation: Cancer Chemother Pharmacol. 2013 Mar;71(3):733-40
references.pmid: 23299794
references.citation: Drug Metab Rev. 2012 May;44(2):148-72
references.pmid: 22497631
references.citation: Curr Opin Pharmacol. 2007 Aug;7(4):367-74
references.pmid: 17681492
references.citation: Anticancer Res. 2008 May-Jun;28(3B):1917-22
references.pmid: 18630481
references.citation: Pharmacogenomics. 2008 Jan;9(1):93-104
references.pmid: 18154451
references.citation: PLoS One. 2013 Nov 08;8(11):e78707
references.pmid: 24250808
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Tumour Biol. 2014 Jan;35(1):247-56
references.pmid: 23888321
references.citation: Cancer Chemother Pharmacol. 2013 Jan;71(1):265-72
references.pmid: 23090619
references.citation: Curr Drug Metab. 2006 Aug;7(6):613-28
references.pmid: 16918316
references.citation: Antioxid Redox Signal. 2012 Dec 15;17(12):1728-37
references.pmid: 22540427
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Br J Cancer. 2004 Jul 19;91(2):344-54
references.pmid: 15213713
references.citation: Int J Clin Exp Med. 2015 Mar 15;8(3):3300-8
references.pmid: 26064219
references.citation: JAMA. 2011 Sep 28;306(12):1352-8
references.pmid: 21954479
references.citation: Eur J Gastroenterol Hepatol. 2013 May;25(5):556-61
references.pmid: 23283303
references.citation: J Clin Oncol. 2010 May 20;28(15):2556-64
references.pmid: 20385995
references.citation: J Cancer Epidemiol. 2009;2009:302047
references.pmid: 20445800
references.citation: Pharmacogenomics. 2006 Jan;7(1):67-88
references.pmid: 16354126
references.citation: Antioxid Redox Signal. 2004 Apr;6(2):289-300
references.pmid: 15025930